NI201000119A - Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. - Google Patents

Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.

Info

Publication number
NI201000119A
NI201000119A NI201000119A NI201000119A NI201000119A NI 201000119 A NI201000119 A NI 201000119A NI 201000119 A NI201000119 A NI 201000119A NI 201000119 A NI201000119 A NI 201000119A NI 201000119 A NI201000119 A NI 201000119A
Authority
NI
Nicaragua
Prior art keywords
kinase
triazolo
inhibitors
synthesis
pyrimidine compounds
Prior art date
Application number
NI201000119A
Other languages
English (en)
Inventor
Ayral-Kaloustian Semiramis
Brooijmans Natasja
Chen Zecheng
Martin Dehnhardt Christoph
Guillermo Delos Santos Efrén
Dos Santos Osvaldo
Mudumbai Venkatesan Aranapakam
Cunera Verheijen Jeroen
Zask Arie
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of NI201000119A publication Critical patent/NI201000119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de 3H-[1,2,3] triazolo [4,5-d] pirimidina de la Fórmula 1 o una sal farmacéuticamente aceptable del mismo, en el que las variables que lo forman son tal como se define en este documento, que incluye composiciones de los compuestos, y los métodos para confeccionar y usar los compuestos.
NI201000119A 2008-01-15 2010-07-14 Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. NI201000119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2108408P 2008-01-15 2008-01-15
US3468008P 2008-03-07 2008-03-07

Publications (1)

Publication Number Publication Date
NI201000119A true NI201000119A (es) 2011-05-04

Family

ID=40377318

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000119A NI201000119A (es) 2008-01-15 2010-07-14 Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.

Country Status (21)

Country Link
US (1) US20090181963A1 (es)
EP (1) EP2252296A1 (es)
JP (1) JP2011510010A (es)
KR (1) KR20100113567A (es)
CN (1) CN102014914A (es)
AP (1) AP2010005346A0 (es)
AU (1) AU2009205501A1 (es)
BR (1) BRPI0906519A2 (es)
CA (1) CA2712267A1 (es)
CO (1) CO6321259A2 (es)
CR (1) CR11568A (es)
DO (1) DOP2010000217A (es)
EA (1) EA201001017A1 (es)
EC (1) ECSP10010346A (es)
IL (1) IL206820A0 (es)
MA (1) MA32341B1 (es)
MX (1) MX2010007746A (es)
NI (1) NI201000119A (es)
SV (1) SV2010003621A (es)
WO (1) WO2009091788A1 (es)
ZA (2) ZA201004603B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2009120094A2 (en) * 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
SG174527A1 (en) * 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
EP3072890B1 (en) * 2009-07-07 2018-10-17 MEI Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
NZ601581A (en) 2010-02-03 2014-03-28 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
BR112014010492A2 (pt) * 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
EP2986298A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112015026247B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
SG11201609139WA (en) * 2014-05-14 2016-11-29 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2017087818A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of Michigan Dual src/p38 kinase inhibitor compounds and their use as therapeutic agents
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
CN110950868B (zh) * 2018-09-27 2022-05-13 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN113549080B (zh) * 2021-08-27 2023-05-16 中国医学科学院放射医学研究所 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途
KR20240015978A (ko) 2022-07-28 2024-02-06 박수산 다층 수력 발전시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate

Also Published As

Publication number Publication date
CO6321259A2 (es) 2011-09-20
SV2010003621A (es) 2011-07-05
AP2010005346A0 (en) 2010-08-31
CA2712267A1 (en) 2009-07-23
ZA201004603B (en) 2011-03-30
JP2011510010A (ja) 2011-03-31
KR20100113567A (ko) 2010-10-21
EP2252296A1 (en) 2010-11-24
IL206820A0 (en) 2010-12-30
MA32341B1 (fr) 2011-06-01
WO2009091788A1 (en) 2009-07-23
MX2010007746A (es) 2010-08-18
BRPI0906519A2 (pt) 2015-07-14
EA201001017A1 (ru) 2011-02-28
ZA201005793B (en) 2011-04-28
CN102014914A (zh) 2011-04-13
ECSP10010346A (es) 2010-08-31
AU2009205501A1 (en) 2009-07-23
US20090181963A1 (en) 2009-07-16
CR11568A (es) 2010-08-11
DOP2010000217A (es) 2010-07-31

Similar Documents

Publication Publication Date Title
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
NI201000060A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA.
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
CU20100229A7 (es) Compuestos triazina como inhibidores mtor y quinasa p13
ECSP088871A (es) Derivados de triazolopirazina
DOP2014000133A (es) Triazolopiridinas sustituidas
SV2011003853A (es) Compuestos organicos
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
DOP2013000244A (es) Triazolopiridinas
ECSP11011258A (es) Pirimidinas fusionadas
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
ECSP12012338A (es) Triazolopiridinas sustituidas
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
ECSP11011172A (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer.
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
AR076053A1 (es) Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
UY30417A1 (es) Derivados de aril y heteroaril-etil-acilguanidina,su preparacion y su aplicacion en terapeutica
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
CU20100148A7 (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
CU20080204A7 (es) Derivados de triazolopirazina
DOP2007000096A (es) Derivados de triazolopirazina
CU20100014A7 (es) Derivados de pirimidina útiles para el tratamiento de enfermedades inflamatorias o alérgicas
CU24174B1 (es) Triazolopiridinas como inhibidores de quinasa mps-1